Home / For Your Practice / Safety (page 2)

Safety

Safety and Error Prevention: Diabetes in Control is committed to error prevention, safety know-how, awareness of lessons learned, voluntary error reporting, and patient compliance. Working in partnership with the Institute for Safe Medication Practice Also, our popular Disasters Averted section will give you more ideas on safety and preventing errors.

Fasting With Diabetes: How Clinicians Can Reduce Hypoglycemia and DKA Risk

Blood glucose monitor, insulin supplies, healthy meal, and dates arranged for safe diabetes fasting management

Patients with diabetes are increasingly exploring fasting for religious, cultural, and metabolic health reasons. From Ramadan observance to intermittent fasting trends, many individuals choose to abstain from food and fluids for extended periods despite potential risks. For clinicians, this creates an important challenge. Simply advising patients not to fast often …

Read More »

GLP-1 Prescribing Without Baseline Data: Are We Skipping Critical Assessments?

Healthcare provider reviewing incomplete patient assessment form with GLP-1 injection pen and lab indicators in a clinical setting

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

Read More »

Reassessing Hypoglycemia Risk in the Era of Modern Therapies

Physician reviewing continuous glucose monitor data with older adult patient showing low blood sugar alert during diabetes consultation

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

Read More »

GLP-1s and Gallbladder Disease: Risk Stratification and Monitoring in 2026

Anatomical model showing inflamed gallbladder with gallstone next to GLP-1 injection pen illustrating GLP-1 gallbladder risk

The expanding use of GLP-1 receptor agonists for type 2 diabetes and obesity has transformed metabolic care. However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety. Rapid weight loss and altered bile composition during treatment may …

Read More »

GLP-1s and Pancreatic Cancer: Reassessing Long-Term Safety Signals

Physician reviewing abdominal CT scan highlighting pancreas with GLP-1 injection pen on desk during clinical consultation

Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …

Read More »

How to Vet Diabetes Devices: A Clinic Checklist for Safe Tech Adoption

A clinic-first diabetes device evaluation checklist to safely assess CGMs, pumps, and health apps for compatibility, security, and patient outcomes.

As diabetes technology evolves at lightning speed, clinics are under increasing pressure to evaluate a growing range of tools—from continuous glucose monitors (CGMs) and insulin pumps to smartphone apps and cloud platforms. But how can healthcare providers make safe, informed decisions about which tools to recommend? A clear, structured diabetes …

Read More »

Mail-Order Mix-Up

During a recent phone follow-up call to one of my patients, a co-worker and I avoided a "Diabetes Disaster." My patient told me that she had received her mail-order refill for "ASPART," but the bottle didn't look the same....

Read More »

Best Plan for Patient May Not Be The Recommended Plan

Female, type 1 diabetes for 42 years, 58 years of age, lives with husband and dog. The patient has hypoglycemic unawareness. We regularly readjust her treatment plan and have recommended CGM for this patient on numerous occasions. Still, she refuses, stating her dog wakes her up if and when she has hypoglycemia. She called to let us know her dog passed away....

Read More »